These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15177844)

  • 1. Antibiotic resistance in the institutionalized elderly.
    Hujer AM; Bethel CR; Hujer KM; Bonomo RA
    Clin Lab Med; 2004 Jun; 24(2):343-61. PubMed ID: 15177844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antibiotic-resistant bacteria in long-term-care facilities: An emerging problem in the practice of infectious diseases.
    Bonomo RA
    Clin Infect Dis; 2000 Dec; 31(6):1414-22. PubMed ID: 11096012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance in long-term care facilities.
    Esposito S; Leone S; Noviello S; Lanniello F; Fiore M
    New Microbiol; 2007 Jul; 30(3):326-31. PubMed ID: 17802920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP
    J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important aspects of nosocomial bacterial resistance and its management.
    Kandelaki G; Tsertsvadze T; Macharashvili N; Esugbaia M; Gogichaishvili Sh
    Georgian Med News; 2008 Dec; (165):49-54. PubMed ID: 19124917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic and infection tracking in Minnesota long-term care facilities.
    O'Fallon E; Harper J; Shaw S; Lynfield R
    J Am Geriatr Soc; 2007 Aug; 55(8):1243-7. PubMed ID: 17661964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance in gram-negative bacteria: enterobacteriaceae.
    Paterson DL
    Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selection and use of cephalosporins: a review.
    Klein NC; Cunha BA
    Adv Ther; 1995; 12(2):83-101. PubMed ID: 10150326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing epidemiology of resistance.
    Hawkey PM; Jones AM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i3-10. PubMed ID: 19675017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the mechanism of resistance to third-generation cephalosporins by class C beta-lactamases by using chemical complementation.
    Carter BT; Lin H; Goldberg SD; Althoff EA; Raushel J; Cornish VW
    Chembiochem; 2005 Nov; 6(11):2055-67. PubMed ID: 16250067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing bacterial isolates and antibiotic sensitivities of purulent dacryocystitis.
    Briscoe D; Rubowitz A; Assia E
    Orbit; 2005 Mar; 24(1):29-32. PubMed ID: 15764113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.